Maryland is currently home to 2677 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
NCT00733590
Recruiting
The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pul... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Heart Failure, Congestive, Death, Sudden, Cardiac, Arrhythmia, Cardiomyopathies
Register for Updates
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
NCT06525571
Recruiting
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Bladder Cancer
Register for Updates
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, the ERASur Study
NCT05673148
Recruiting
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Register for Updates
Gender Related Coping and Survivorship for Genitourinary Cancers
NCT05649306
Recruiting
This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction. This study is a non-therapeutic study and will randomize participants to a standard of care group and education group. Patients in both groups will be asked to complete surveys regarding their mood and sexual function. Patients in the intervention group will be asked to complete attendance diaries regarding educational and supp... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Bladder Cancer
Register for Updates
Scrambler Therapy for Post-Stroke Pain
NCT05563038
Recruiting
The Investigators will enroll patients who have had a stroke and are experiencing post-stroke pain secondary to their infarct and disruption of the sensory system in a research study to compare the effectiveness of Scrambler Therapy to traditional pharmacologic therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Johns Hopkins Bayview Hospital, Baltimore, Maryland
Conditions: Post Stroke Pain
Register for Updates
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
NCT05189262
Recruiting
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/09/2025
Locations: Center for Blood Oxygen Transport and Hemostasis, Baltimore, Maryland
Conditions: Cardiopulmonary Bypass, Cardiac Surgery, Kidney Injury, Acute
Register for Updates
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Conventional Chondrosarcoma
Register for Updates
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04658147
Recruiting
The purpose of this study is to determine the safety and tolerability of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Hepatocellular Carcinoma
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Luminis Health Anne Arundel Medical Center, Annapolis, Maryland
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
NCT03861676
Recruiting
The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease. In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy data) will not be targeted and receive only fall-off dose, which we have shown to be associated with reductions... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
01/09/2025
Locations: SKCCC at Johns Hopkins, Baltimore, Maryland
Conditions: Prostate Cancer
Register for Updates
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
NCT00181233
Recruiting
Sudden cardiac death is a tragic event that strikes all age groups and is unfortunately increasing in prevalence. Because it is difficult to predict those at highest risk, this study is designed to test the hypothesis that new imaging techniques (magnetic resonance imaging \[MRI\] and computed tomography \[CT\]) are useful for identifying factors which put people at high risk for sudden death.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Sudden Cardiac Death
Register for Updates
Ketamine for Multiple Sclerosis Fatigue
NCT05378100
Recruiting
The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/08/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Multiple Sclerosis Fatigue
Register for Updates